Abstract:OBJECTIVE:To assess the efficacy and pathological change of fertility-sparing treatment with progestin for endometrial carcinoma (EC) of stage I a and complex atypical hyperplasia (CAH) and to observe the prognosis of the treatment.METHODS:Nine EC patients of stage I a and 21 CAH patients aged under 40 years who desired childbearing and retaining their fertility were enrolled into this study. All patients were given a daily oral high-dose of progestin with duration of treatment ranging from 6 to 9 months. Diagnostic curettage was performed every 3 months as a modality for seeing the histologic change of neoplastic tissues and endometrial tissue. A careful and long- term follow- up is necessary for patients with complete response (CR).RESULTS:During the first period of fertility-sparing management, according to histologic change, 5 EC patients and 18 CAH patients showed CR with no evidence of endometrial adenocarcinoma or hyperplasia, 2 EC patients and 2 CAH patients showed partial response with a regression to complex or simple hyperplasia without atypia, 2 EC patients and 1 CAH patient showed stable disease or progressive disease. Accordingly, a total of 26 patients showed CR (26 of 30 patients). The median time to CR was 6 months (range, 3 to 21 months) of progestin treatment. The median follow-up time was 55.5 months (range, 24 to 104 months) and all patients were alive. During follow-up, among the 26 patients with CR, 3 of 6 EC patients achieved CR recurred disease after a median time interval of 10 months (range, 6 to 51 months), 7 of 20 CAH patients achieved CR had recurrent disease after a median time interval of 12 months (range, 6 to 55 months). Four of 7 CAH with recurrent disease achieved CR to progestin re-treatment. Eight of 26 patients achieved CR continued a further 3 or 6 months of consolidation therapy, 3 of them had recurrent disease, the remaining 18 stopped progesterone treatment after CR and 7 patients had recurrent disease; there was no significant statistical difference between the two groups (P = 1.000). EC patients succeeded in 4 pregnancies, CAH patients succeeded in 10 pregnancies, they gave birth to 16 healthy babies in all.CONCLUSIONS:EC of stage I a and CAH had slow progression of symptoms. Progestin treatment in EC of stage I a and CAH patients was effective. A careful and long-term follow-up is required because of the substantial high rate of recurrence. Progestin re-treatment in most patients with recurrent endometrial cancer is effective and safe.

Transcervical resection of endometrium for inhibition of proliferative response of endometrium in women with breast cancer on adjuvant tamoxifen

Outcome of Conservative Treatment and Subsequent Assisted Reproductive Technology for Patients with Early-Stage Endometrial Adenocarcinoma and Poor Fertility Potential

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Evaluation on Surgical Curative Effect of Atypical Hyperplasia of Endometrium

Efficacy of Transcervical Resection of Endometrium for Adenomyosis

[Analysis of the Efficiency of Transcervical Resection of Endometrium for Treating Dysfunctional Uterine Bleeding and Factors Reducing the Efficiency of the Operation].

Microwave Endometrial Ablation for Endometrial Protection in Women with Breast Cancer on Adjuvant Tamoxifen

The Variety of Expressions of Microvessel Density, Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor (KDR) in Endometrium Before and after Transcervical Resection of Endometrium

A randomized controlled clinical trial:the treatment effects of tamoxifen on patients with thin endometrium undergoing frozen-thawed embryo transfer

Clinical observation on hysteroscopic transcervical resection of endometrium combined with levonorgestrel-releasing intrauterine system in treatment of adenomyosis

[Effects of Pathological Assessment of Endometrial Tissue in Fertility-Sparing Treatment with Progestin for Endometrial Carcinoma of Stage I a and Complex Atypical Hyperplasia].

Relationship Between the Expression of PTEN, ER and PR and the Prognosis of TCRE in Endometrial Hyperplasia

The clinic-pathology of gynecological complications in 134 cases of breast cancer

Combined Effects of Goserelin and Tamoxifen on Estradiol Level, Breast Density, and Endometrial Thickness in Premenopausal and Perimenopausal Women with Early-Stage Hormone Receptor-Positive Breast Cancer: a Randomised Controlled Clinical Trial.

Chinese Medicinal Plants for Advanced Endometriosis after Conservative Surgery: A Prospective, Multi-Center and Controlled Trial

The expression of estrogen and progesterone receptors in the endometrial polyps in postmenopausal women and its effect on therapy

Expressions of Ki67,estrogen receptor,and progestogen receptor in endometrium of patients with breast cancer after oral administration of Tamoxifen and the changes of sex hormones levels

Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen

The Effects of Tamoxifen on Cervix of the Breast Cancer Patients

[Transcervical Resection of Myoma in Treatment of Hysteromyoma, Experience in 962 X\cases].

Hypomethylation Associated Enhanced Transcription of Trefoil Factor-3 Mediates Tamoxifen-Stimulated Oncogenicity of ER+ Endometrial Carcinoma Cells